| Antiangiogenic drugs in non-small cell lung cancer treatment. | |
| | |
MedLine Citation:
|
PMID: 16462184 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
PURPOSE OF REVIEW: A promising therapeutic target is the vascular endothelial growth factor pathway - a key mediator of tumor angiogenesis - which is important in tumor growth, invasion, and metastasis. This review focuses on the available clinical data on drugs targeting the vascular endothelial growth factor - vascular endothelial growth factor receptor pathway in the treatment of non-small cell lung cancer. RECENT FINDINGS: The therapeutic value of inhibiting the vascular endothelial growth factor pathway has been demonstrated by using drugs that prevent vascular endothelial growth factor receptor binding and by using drugs that inhibit receptor activation. Two antiangiogenic drugs exemplify these mechanisms: bevacizumab (Avastin; Genentech, South San Francisco, California, USA), a humanized monoclonal antibody that acts by binding and neutralizing vascular endothelial growth factor; and ZD6474 (Zactima; AstraZeneca, Macclesfield, UK), a small-molecule inhibitor of vascular growth factor receptor and epidermal growth factor receptor tyrosine kinase activity. Recently, the first results of a large, phase III randomized clinical trial of bevacizumab in combination with platinum-based doublet chemotherapy have been reported in patients with nonsquamous non-small cell lung cancer. SUMMARY: The inhibition of tumor angiogenesis is a key therapeutic strategy that holds great promise for the advancement of metastatic lung cancer therapy. The combination of bevacizumab and conventional chemotherapy could offer a new therapeutic option in selected non-small cell lung cancer histotypes. |
| | |
Authors:
|
Tina Cascone; Teresa Troiani; Maria Pia Morelli; Cesare Gridelli; Fortunato Ciardiello |
Related Documents
:
|
2678104 - Production of platelet-derived endothelial cell growth factor by normal and transformed... 12049814 - Novel benzimidazole derivatives selectively inhibit endothelial cell growth and suppres... 12762884 - Glioblastoma and cerebral microvascular endothelial cell migration in response to tumor... 18698224 - Vascular endothelial growth factor, left ventricular dysfunction and mortality in hemod... 9235944 - Alpha4 integrin binding interfaces on vcam-1 and madcam-1. integrin binding footprints ... 14556284 - Methylene blue blocks cgmp production and disrupts directed migration of microglia to n... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Current opinion in oncology Volume: 18 ISSN: 1040-8746 ISO Abbreviation: Curr Opin Oncol Publication Date: 2006 Mar |
Date Detail:
|
Created Date: 2006-02-07 Completed Date: 2006-09-28 Revised Date: 2009-11-19 |
Medline Journal Info:
|
Nlm Unique ID: 9007265 Medline TA: Curr Opin Oncol Country: United States |
Other Details:
|
Languages: eng Pagination: 151-5 Citation Subset: IM |
Affiliation:
|
Cattedra di Oncologia Medica, Dipartimento Medico-Chirurgico di Internistica Clinica e Sperimentale F Magrassi e A Lanzara, Seconda Università degli Studi di Napoli, Naples, Italy. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Angiogenesis Inhibitors
/
therapeutic use* Antibodies, Monoclonal / therapeutic use Antineoplastic Agents / therapeutic use Carcinoma, Non-Small-Cell Lung / drug therapy* Drug Therapy, Combination Humans Lung Neoplasms / drug therapy* Piperidines / therapeutic use Protein-Tyrosine Kinases / drug effects Quinazolines / therapeutic use Receptor, Epidermal Growth Factor / drug effects Receptors, Vascular Endothelial Growth Factor / drug effects Vascular Endothelial Growth Factor A / antagonists & inhibitors, drug effects |
| Chemical | |
Reg. No./Substance:
|
0/Angiogenesis Inhibitors; 0/Antibodies, Monoclonal; 0/Antineoplastic Agents; 0/N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine; 0/Piperidines; 0/Quinazolines; 0/Vascular Endothelial Growth Factor A; EC 2.7.10.1/Protein-Tyrosine Kinases; EC 2.7.10.1/Receptor, Epidermal Growth Factor; EC 2.7.10.1/Receptors, Vascular Endothelial Growth Factor |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Advances in our understanding of postoperative adjuvant chemotherapy in resectable non-small-cell lu...
Next Document: New developments in chemotherapy for advanced non-small cell lung cancer.